BiotechTube

SPIKEVAX

PreclinicalCompleted
1 views this week 0 watching
0
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SARS-CoV-2

Conditions

SARS-CoV-2

Trial Timeline

Apr 14, 2023 → Feb 29, 2024

NCT ID
NCT06130345

About SPIKEVAX

SPIKEVAX is a preclinical stage product being developed by Moderna for SARS-CoV-2. The current trial status is completed. This product is registered under clinical trial identifier NCT06130345. Target conditions include SARS-CoV-2.

What happened to similar drugs?

4 of 20 similar drugs in SARS-CoV-2 were approved

Approved (4) Terminated (1) Active (16)
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1083ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1273.211ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
✅mRNA-1273 Variant-containing FormulationModernaApproved

Clinical Trials (3)

NCT IDPhaseStatus
NCT06130345PreclinicalCompleted
NCT06369272PreclinicalCompleted
NCT06189053PreclinicalActive

Competing Products

20 competing products in SARS-CoV-2

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1273ModernaPhase 1
0
mRNA-1283ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1273.214ModernaPhase 2
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1083.1ModernaPhase 2
0
SPIKEVAX BivalentModernaPreclinical
0
mRNA-1083ModernaPhase 3
0
mRNA-1273ModernaPhase 2
0
mRNA-1073ModernaPhase 2
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1273.211ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0
mRNA-1083ModernaPhase 2
0